Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Pass Above 200-Day Moving Average – Here’s Why

Posted by Jeff Wilder on May 16th, 2026

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.62 and traded as high as $3.68. Cryo-Cell International shares last traded at $3.62, with a volume of 2,605 shares changing hands.

Cryo-Cell International Price Performance

The company has a market capitalization of $29.18 million, a price-to-earnings ratio of -10.97 and a beta of 0.49. The stock has a fifty day simple moving average of $3.43 and a 200-day simple moving average of $3.62.

Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $7.68 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent reporting period. Institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

(Get Free Report)

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.